The Latest Breaking News from Novo Nordisk

Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners

Pharmac’s decision to fund continuous glucose monitors and automated insulin delivery systems for the approximately 18,000 people who currently live with type 1 diabetes in Aotearoa New Zealand is good news.

Stock picking is the hallmark of top mutual fund T. Rowe Price U.S. Equity Research Fund.

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Novo Nordisk stock fell after a JPMorgan analyst said sales of its blockbuster weight-loss drug may be weaker-than-expected.

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes. Recently, it has been in the spotlight due to lawsuits being filed against its manufacturer, Novo Nordisk. These lawsuits claim that Ozempic has been linked to a serious gastrointestinal condition called gastroparesis.

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.